EGFR and non-small cell lung carcinoma: Preclinical studies have suggested that EGFR signalling could play a central role in reducing RET inhibitors’ efficacy in NSCLC cell lines, thus providing a rationale for co-targeting both EGFR and RET in order to reduce the onset of drug resistances.